CN105330582A - Preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide - Google Patents
Preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide Download PDFInfo
- Publication number
- CN105330582A CN105330582A CN201410386909.5A CN201410386909A CN105330582A CN 105330582 A CN105330582 A CN 105330582A CN 201410386909 A CN201410386909 A CN 201410386909A CN 105330582 A CN105330582 A CN 105330582A
- Authority
- CN
- China
- Prior art keywords
- esomeprazole
- preparation
- reaction
- intermediate compound
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides a preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide. The preparation method comprises the following steps: (1) with R-4-chloro-3-hydroxy butyrate as an initial raw material, subjecting the initial raw material and an azido reaction agent to an azido reaction so as to obtain an intermediate I; (2) subjecting the intermediate I to a reduction reaction so as to obtain an intermediate II; (3) subjecting the intermediate II and halogenated acetate to a condensation reaction so as to obtain an intermediate III; (4) subjecting the intermediate III to a ring closure reaction so as to obtain an intermediate IV; and (5) subjecting the intermediate IV to an aminolysis reaction so as to obtain (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide. The preparation method can prepare a (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide product with ideal yield of at least more than 38%, and a novel synthetic route is opened up for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide.
Description
Technical field
The present invention relates to (R)-Esomeprazole, particularly relate to the preparation method of one (R)-Esomeprazole.
Background technology
Oxiracetam is the nootropics synthesized first in 1974 than Qie Mu company by Italian SmithKline, is a kind of hydroxy-amino-butyric acid (GABOB) derivative, can promote study, memory, the medicine for central nervous system of protection damaged nerve cell.(R)-Esomeprazole is the dextrorotatory form of oxiracetam; report is had to show that the activity of oxiracetam levo form is higher than dextrorotatory form; but still there is the curative effect of central nervous system aspect promoting very by force study, memory, protection damaged nerve cell in dextrorotatory form, and has important market in the reference substance of levo-oxiracetam is applied.
In current dextrorotation oxiracetam synthetic route, be all adopt the mode of column chromatography or ion exchange resin to obtain high purity target compound substantially, this is unfavorable for suitability for industrialized production.And need strong alkali environment in building-up process, this easily makes dextrorotation oxiracetam be destroyed, and foreign matter content increases; Contriver finds under study for action, and use disclosed document synthesis dextrorotation oxiracetam at present, in end product, the content of enantiomer is higher, does not meet needs that are clinical and inspection.
Summary of the invention
The object of the present invention is to provide the synthetic method of one (R)-Esomeprazole, the method is applicable to suitability for industrialized production.
Goal of the invention of the present invention is achieved by the following technical solution:
A kind of synthetic method of (R)-Esomeprazole, is characterized in that, comprise the steps:
(1) with R-4-chloro-3-hydroxybutanoic acid ester for starting raw material, carry out azido reaction, obtain intermediate compound I;
(2) intermediate compound I is carried out reduction reaction and obtain intermediate II;
(3) intermediate II and halogenated acetic acids ester are carried out condensation reaction, obtain intermediate III;
(4) intermediate III is carried out ring closure reaction and obtain intermediate compound IV;
(5) intermediate compound IV is carried out ammonolysis reaction, obtain target product (R)-Esomeprazole.
Reaction expression is as follows:
Above-mentioned R1 is the alkyl of C1-C6, phenyl or benzyl.R2 is the alkyl of C1-C6, phenyl or benzyl.
The alkyl preferable methyl of described C1-C6, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, cyclopentyl or cyclohexyl.
The azide reagent that above-mentioned steps (1) azido reaction uses is sodiumazide, one or more mixing in Lithium Azide, potassium azide, azide calcium, barium azide.
The reduction reaction of above-mentioned steps (2) select in borohydride reduction or hydrogen reducing any one.
Above-mentioned hydroborate can be the one or more combination in sodium borohydride, POTASSIUM BOROHYDRIDE.
The catalyzer of above-mentioned hydrogen reducing is metal catalyst, one or more combinations in palladium, rhodium, platinum.
Above-mentioned halogenated acetic acids ester is chloracetic acid ester or monobromo-acetic acid ester.
In order to make, impurity is more easily separated, operation steps is simple, thus obtain the industrialization of high-purity product, promotion pharmaceutical production, also ensure reaction yield simultaneously, chloracetic acid ester in above-mentioned steps (3) adopts ethyl chloroacetate, and monobromo-acetic acid ester adopts ethyl bromoacetate, the positive butyl ester of bromoacetic acid, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide.
In above-mentioned above-mentioned steps (3), condensation reaction can use alkaline condition, as the one or more combination in pyridine, triethylamine, lutidine, salt of wormwood or sodium bicarbonate.
In order to improve reactive behavior further thus improve reaction yield further, the solvent of above-mentioned (1) step can select methyl alcohol, ethanol, n-propyl alcohol, Virahol, propyl carbinol, ethyl acetate, hexalin, cyclopentanol, DMF, DMSO, preferably adopts DMF, DMSO, ethanol or cyclopentanol.
Intermediate compound I general formula is as follows:
R1 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, cyclopentyl or cyclohexyl etc.
In order to further improve reactive behavior, improve reaction yield, the mol ratio of above-mentioned azide reagent and R-4-chloro-3-hydroxybutanoic acid ester is: R-4-chloro-3-hydroxybutanoic acid ester: azide reagent or catalyzer=1: 1 ~ 2.5.
More particularly, above-mentioned (1) step is:
First by the above-mentioned solvent of R-4-chloro-3-hydroxybutanoic acid ester and 5 ~ 20 times of weight, then add above-mentioned azide reagent and react 1 ~ 5 hour at 0 ~ 160 DEG C, R-4-chloro-3-hydroxybutanoic acid ester and azide reagent mol ratio are 1: 1 ~ 2.5; Obtain the solution containing intermediate compound I, then collect intermediate compound I from containing the solution of intermediate compound I.
Above-mentioned R-4-chloro-3-hydroxybutyrate ester, solvent and azide reagent are commercially available prod.
Above-mentioned (2) step, specifically, be the intermediate compound I will obtained from step (1), in a solvent and metal catalyst exist under carry out reduction reaction 5 ~ 10 hours with hydrogen, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate II; Described solvent is without particular requirement, and one or more in prioritizing selection methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO, EA combine; Said metal catalyst is preferably one or more combinations in palladium, rhodium, platinum.
In order to further improve reaction purity and yield, the weight ratio of intermediate compound I and solvent is: 1: 10 ~ 15, and the weight ratio of intermediate compound I and described metal catalyst is: 1: 0.1 ~ 0.5.
The most specifically, above-mentioned (2) step, it is the intermediate compound I that will obtain from step (1), in the solvent of the 10-15 times of weight of R-4-chloro-3-hydroxybutanoic acid ester under metal catalyst exists with hydrogen reaction 5 ~ 10 hours, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate II; Described solvent is without particular requirement, and one or more in prioritizing selection methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO combine; Said metal catalyst is preferably one or more combinations in palladium, rhodium, platinum; The weight ratio of intermediate compound I and solvent is: 1: 10 ~ 15, and the weight ratio of intermediate compound I and described metal catalyst is: 1: 0.1 ~ 0.5.
Intermediate II general formula is as follows:
R1 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, cyclopentyl or cyclohexyl etc.
Above-mentioned (3) step, specifically, be the intermediate II will obtained from step (2), react 5 ~ 10 hours in a solvent with halogenated acetic acids ester under alkaline catalysts exists, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate III; Described solvent is without particular requirement, and one or more in prioritizing selection methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO combine; Said alkaline catalysts is preferably pyridine, triethylamine, lutidine, salt of wormwood or sodium bicarbonate.
In order to further improve reaction purity and yield, the mol ratio of intermediate II and halogenated acetic acids ester is: 1: 1 ~ 3, and the mol ratio of intermediate II and described alkaline catalysts is: 1: 2 ~ 3.
The most specifically, above-mentioned (3) step, it is the intermediate II that will obtain from step (2), under alkaline catalysts exists, 5 ~ 10 hours are reacted with halogenated acetic acids ester in the solvent of the 10-15 times of weight of R-4-chloro-3-hydroxybutyrate ester, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate III; Described solvent is without particular requirement, and one or more in prioritizing selection methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO combine; Described alkaline catalysts is preferably the one in pyridine, triethylamine, lutidine, salt of wormwood or sodium bicarbonate; The mol ratio of intermediate II and halogenated acetic acids ester is: 1: 1 ~ 3, and the mol ratio of intermediate II and described alkaline catalysts is: 1: 2 ~ 3.
Intermediate III general formula is as follows:
R1 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, cyclopentyl or cyclohexyl etc.; R2 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, benzyl or cyclopentyl etc.
Above-mentioned steps (4), specifically, by the intermediate III that step (3) obtains, ring closure reaction is carried out in a solvent under 50 ~ 130 DEG C of conditions, time is 3 ~ 8 hours, obtaining the solution containing intermediate compound IV, then obtaining intermediate compound IV from containing collecting the solution of intermediate compound IV; Described solvent can be selected: ethanol, the trimethyl carbinol, toluene, dimethylbenzene, water, ethyl acetate, butylacetate or ethyl butyrate, preferably adopts ethanol, toluene or dimethylbenzene.
Intermediate compound IV general formula is as follows:
R2 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, benzyl or methoxybenzyl etc.
In order to further improve reaction purity and yield, the mol ratio of intermediate III and solvent is 1: 10 ~ 30.
Above-mentioned steps (5), specifically, by the intermediate compound IV that step (4) obtains, at 20 ~ 30 DEG C, react 4 ~ 16 hours with strong aqua, from reaction product, then collect target product (R)-Esomeprazole.
In order to improve reactive behavior further thus improve overall yield of reaction, above-mentioned intermediate compound IV: the mol ratio of ammonia is intermediate compound IV: ammonia=1: 12 ~ 15, in the ammonia in ammonia methanol solution; Described strong aqua is well known in the art, and the concentrations by weight of its solution is about 25 ~ 28%.
The method of target product (R)-Esomeprazole is collected from the reaction product of above-mentioned steps (5), preferably as follows: reaction product is dissolved in the water, heating for dissolving, activated carbon decolorizing, cross and filter gac, concentrating under reduced pressure dewaters, when surplus water is concentrated for stopping when adding products weight 2 ~ 3 times, 0 ~ 5 DEG C of subcooling crystallization, obtains to obtain product (R)-Esomeprazole.
In particular, the method for (R)-Esomeprazole prepared by one, adopts following steps:
(1), first by the solvent of R-4-chloro-3-hydroxybutanoic acid ester and 5 ~ 20 times of weight, then add azide reagent to react 1 ~ 5 hour at 0 ~ 60 DEG C, R-4-chloro-3-hydroxybutanoic acid ester and azide reagent mol ratio are 1: 1.5 ~ 2.5, obtain the solution containing intermediate compound I, then collect intermediate compound I from containing the solution of intermediate compound I; Described solvent is the one in ethanol, cyclopentanol, DMF, DMSO;
(2), the intermediate compound I that will obtain from step (1), in a solvent and carry out reduction reaction 7 ~ 9 hours with hydrogen under metal catalyst exists, temperature of reaction is 30 ~ 50 DEG C, then collects and obtains intermediate II; One or more combinations in described solvent selected from methanol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO, EA; Said metal catalyst is one or more combinations in palladium, rhodium, platinum;
(3) intermediate II that, will obtain from step (2), under alkaline catalysts exists, 5 ~ 10 hours are reacted with halogenated acetic acids ester in the solvent of the 10-15 times of weight of R-4-chloro-3-hydroxybutanoic acid ester, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate III; One or more combinations in described solvent selected from methanol, ethanol, Virahol, tetrahydrofuran (THF), DMF, DMSO, described alkaline catalysts is selected from pyridine, triethylamine, lutidine, salt of wormwood or sodium bicarbonate, and described halogenated acetic acids ester is the one in ethyl bromoacetate, ethyl chloroacetate, the positive butyl ester of bromoacetic acid, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide; The mol ratio of described intermediate II and halogenated acetic acids ester is: 1: 1 ~ 3, and the mol ratio of intermediate II and described alkaline catalysts is: 1: 2 ~ 3;
(4), be intermediate III step (3) obtained, ring closure reaction is carried out in a solvent under 50 ~ 130 DEG C of conditions, time is 3 ~ 8 hours, obtains the solution containing intermediate compound IV, then obtains intermediate compound IV from containing collecting the solution of intermediate compound IV; One in described solvent selected from ethanol, toluene, dimethylbenzene, the mol ratio of described intermediate II and solvent is 1: 10 ~ 30;
(5) intermediate compound IV, by step (4) obtained, reacts 4 ~ 16 hours with strong aqua at 20 ~ 30 DEG C, obtains reaction product (R)-Esomeprazole crude product; Described intermediate compound IV: the mol ratio of ammonia is intermediate compound IV: ammonia=1: 12 ~ 15, in the ammonia in ammonia methanol solution;
(6), (5) step gained reaction product is dissolved in the water, heating for dissolving, activated carbon decolorizing, cross and filter gac, concentrating under reduced pressure dewaters, when surplus water is concentrated for stopping when adding products weight 2 ~ 3 times, 0 ~ 5 DEG C of subcooling crystallization, obtains product (R)-Esomeprazole.
The present invention has following beneficial effect:
1, the present invention adopts R-4-chloro-3-hydroxybutanoic acid ester and azide reagent to be starting raw material, raw material suitability for industrialized production in a large number, is easy to buy and low price; Circuit is simple, and intermediate and product all do not need column chromatography, and cost is low, easy and simple to handle, is applicable to industrialized production.
2, in cyclization process of the present invention, do not need strong alkali environment, decrease the generation of impurity in reaction.
3, the present invention is not when needing column chromatography, (the R)-Esomeprazole product purity obtained detects through high performance liquid phase and reaches more than 99.9%, and total recovery is more than 38%, reach as high as 43%, and isomer proportion is less than 0.1%, optical purity more than 99.9%.
The present invention opens a new dextrorotation oxiracetam synthetic route.
Embodiment
Below by embodiment, the present invention is specifically described; what be necessary to herein means out is; following examples are only for being further detailed the present invention; can not be interpreted as limiting the scope of the invention, the person skilled in the art in this field can make some nonessential improvement and adjustment according to foregoing invention content to the present invention.Agents useful for same of the present invention is commercially available prod.
Embodiment 1
A kind of synthetic method of (R)-Esomeprazole, it carries out as follows,
(1) preparation of intermediate compound I:
Get raw material R-4-chloro-3-hydroxyl methyl-butyrate 50g, add in a single neck bottle, add DMF50ml, stir, ice-water bath cools, and adds sodiumazide 50g, keeps temperature to be no more than 40 DEG C, is warming up to 60 DEG C after adding.React 2 hours, stopped reaction obtains yellow solution.Add water 100ml, with ethyl acetate 100ml extraction, concentrated removing ethyl acetate, obtains yellow oil intermediate compound I.Detect through nuclear-magnetism, intermediate compound I is: 1H-NMR (300MHz, CDCl3): δ 1.42-1.73 (m, 2H) 2.76-2.67 (ABsystem, m, 2H,), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 3.70 (s, 1H). intermediate compound I is:
r1 is methyl.
(2) preparation of intermediate II
The intermediate compound I that step (2) obtains is dissolved in the methyl alcohol of 500ml, is cooled to outer temperature 0 DEG C, add 10% palladium-carbon catalyst 10g, pass into stirring under hydrogen 5 hours, point plate is shown in that raw material reaction is complete, stopped reaction, concentrates except desolventizing obtains pale yellow oil intermediate II.Detect through nuclear-magnetism, intermediate II: 1H-NMR (300MHz, D2O): δ 2.76-2.67 (ABsystem, m, 2H), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 4.70 (bs, 3H) .13C-NMR (50MHz, D2O): δ 43.7 (C-2), 48.4 (C-4), 57.0 (OCH), 68.9 (C-3), 177.5 (C-I). intermediate II is
r1 is methyl.
(3) preparation of intermediate III
The intermediate II that step (2) obtains is dissolved in the methyl alcohol of 500ml, be cooled to outer temperature 0 DEG C, add salt of wormwood 173g (3eq), a large amount of solid is had to generate, stir five minutes, start to drip ethyl bromoacetate 90ml (2eq), dropping process has exothermic phenomenon, dropwise rear continuation stirring 2 hours, point plate is shown in that raw material reaction is complete, stopped reaction, add EA (ethyl acetate) 500ml, water 300ml, solid dissolves completely, by saturated for water layer solid sodium chloride, separate organic layer, water layer EA200ml extracting twice, merge organic layer, the hydrochloric acid 200ml of organic layer 2M washes three times, merge hydrochloric acid aqueous phase, organic phase discards, aqueous phase continuation sodium bicarbonate regulates pH to 8, solid sodium chloride is saturated, EA300ml extracts three times, merge organic phase, anhydrous magnesium sulfate drying, concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate III.Detect through nuclear-magnetism, intermediate III: 1H-NMR (300MHz, D20): δ 1.3 (t, 3H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s, 2H), 3.67 (s, 3H), 4.09-4.12 (m, 3H). intermediate III is
r1 is methyl, and R2 is ethyl.
(4) preparation of intermediate compound IV
By the intermediate III 500ml dissolve with ethanol that step (2) obtains, be warming up to 75 DEG C, reflux 8 hours, obtain a red tan solution, some plate is shown in that raw material reaction is complete.Stopped reaction, concentrated removing ethanol, adds EA (ethyl acetate) and dissolves, cross and filter salt, activated carbon decolorizing, concentrate and remove yellow oil obtains intermediate compound IV.Detect through nuclear-magnetism, intermediate compound IV is: 1H-NMR (300MHz, CDCl3) δ 1.280 (t, 3H), 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H). intermediate compound IV:
r2 is ethyl.
(5) preparation of (R)-Esomeprazole
The intermediate compound IV that step (4) obtains is added strong aqua 200ml, stirring at room temperature 18 hours, some plate is shown in that raw material reaction is complete, stopped reaction, concentrated removal water and ammonia, obtain yellow oil, add acetone solution oily matter, add a small amount of crystal seed and stir, separate out solid, a small amount of acetone rinsing bottle wall ,-10 DEG C of crystallizations 5 hours, filter and obtain off-white color crude product 24g.Purity 99.3%, isomer proportion 0.2%.By this dissolving crude product in the water of 100ml, heating makes it dissolve, and activated carbon decolorizing half an hour, cross and filter gac, crystallisation by cooling, 5 DEG C of placements are spent the night, and filter to obtain white solid 22g next day, purity 99.9%, isomer proportion 0.1%.Detect through nuclear-magnetism, dextrorotation oxiracetam: 1H-NMR (300MHz, DMSO-d6) δ 2.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.3.(R)-Esomeprazole is that structural formula is as follows:
Embodiment 2
A kind of synthetic method of (R)-Esomeprazole, it carries out as follows,
(1) preparation of intermediate compound I:
Take R-4-chloro-3-hydroxyl methyl-butyrate 50kg, add in the azido reaction still of 500L, add DMF50L, stir, chuck leads to ice-water bath cooling, adds sodiumazide 50Kg, keep temperature to be no more than 40 DEG C, pressure is except the frozen water in chuck, and chuck leads to hot water makes interior temperature be warming up to 60 DEG C.React 2 hours, stopped reaction obtains yellow solution.Add water 100L in still, by ethyl acetate 100L extraction, separatory aqueous phase discarded, organic phase concentrated removing ethyl acetate, obtains yellow oil intermediate compound I.Detect through nuclear-magnetism, intermediate compound I is: 1H-NMR (300MHz, CDCl3): δ 1.42-1.73 (m, 2H) 2.76-2.67 (ABsystem, m, 2H,), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 3.70 (s, 1H). intermediate compound I is:
r1 is methyl.
(2) preparation of intermediate II
The intermediate compound I that step (2) obtains is dissolved in the methyl alcohol of 500L, be transferred in the hydrogenation reaction cauldron of 1000L, chuck leads to icy salt solution and is cooled to interior temperature 0 DEG C, add 10% palladium-carbon catalyst 10kg, pass into stirring under hydrogen 5 hours, get in sample and control Liquid Detection and see that raw material reaction is complete, stopped reaction, concentratedly obtain pale yellow oil intermediate II except desolventizing.Detect through nuclear-magnetism, intermediate II: 1H-NMR (300MHz, D2O): δ 2.76-2.67 (ABsystem, m, 2H), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 4.70 (bs, 3H) .13C-NMR (50MHz, D2O): δ 43.7 (C-2), 48.4 (C-4), 57.0 (OCH), 68.9 (C-3), 177.5 (C-I). intermediate II is
r1 is methyl.
(3) preparation of intermediate III
The intermediate II that step (2) obtains is dissolved in the methyl alcohol of 500L, be transferred in the condensation reaction still of 1500L, join 150L and drip one, tank, in chuck, logical frozen water is cooled to outer temperature 0 DEG C, add salt of wormwood 173kg (3eq), a large amount of solid is had to generate, stir five minutes, ethyl bromoacetate press-in is dripped tank, start to drip ethyl bromoacetate 90L (2eq), dropping process has exothermic phenomenon, dropwise rear continuation stirring 2 hours, get in sample and control Liquid Detection and see that raw material reaction is complete, stopped reaction, add EA (ethyl acetate) 500L, water 300L, solid dissolves completely, by saturated for water layer solid sodium chloride, separate organic layer, water layer proceeds to extractor, continue to use EA200L extracting twice, merge organic layer, the hydrochloric acid 200L of organic layer 2M washes three times, merge hydrochloric acid aqueous phase, proceed to extractor, organic phase discards, aqueous phase continuation sodium bicarbonate in extractor regulates pH to 8, solid sodium chloride is saturated, EA300L extracts three times, merge organic phase, anhydrous magnesium sulfate drying, concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate III.Detect through nuclear-magnetism, intermediate III: 1H-NMR (300MHz, D2O): δ 1.3 (t, 3H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s, 2H), 3.67 (s, 3H), 4.09-4.12 (m, 3H). intermediate III is
r1 is methyl, and R2 is ethyl.
(4) preparation of intermediate compound IV
By the intermediate III 500L dissolve with ethanol that step (2) obtains, proceed to the cyclization still of 1000L, chuck leads to hot water and is warming up to interior temperature 75 DEG C, refluxes 8 hours, obtains a red tan solution, gets in sample to control Liquid Detection and see that raw material reaction is complete.Stopped reaction, concentrated removing ethanol, adds EA (ethyl acetate) 200L and dissolves, cross and filter salt, activated carbon decolorizing, concentrate and remove yellow oil obtains intermediate compound IV.Detect through nuclear-magnetism, intermediate compound IV is: 1H-NMR (300MHz, CDCl3) δ 1.280 (t, 3H), 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H). intermediate compound IV:
r2 is ethyl.
(5) preparation of (R)-Esomeprazole
The intermediate compound IV that step (4) obtains is added strong aqua 200L, proceeds in the ammonolysis reaction still of 500L, stirring at room temperature 18 hours, get in sample and control Liquid Detection and see that raw material reaction is complete, stopped reaction, concentrated removal water and ammonia, obtain yellow oil, add acetone 100L and dissolve oily matter, add a small amount of crystal seed to stir, separate out solid, 10L acetone rinsing still wall,-10 DEG C of crystallizations 5 hours, filter and obtain off-white color crude product 24kg.Purity 99.3%, isomer proportion 0.2%.By this dissolving crude product in the water of 100L, heating makes it dissolve, and activated carbon decolorizing half an hour, cross and filter gac, crystallisation by cooling, 5 DEG C of placements are spent the night, and filter to obtain white solid 22kg next day, purity 99.9%, isomer proportion 0.05%.Detect through nuclear-magnetism, dextrorotation oxiracetam: 1H-NMR (300MHz, DMSO-d6) δ 2.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.3.(R)-Esomeprazole is that structural formula is as follows:
Embodiment 3
1, a kind of synthetic method of (R)-Esomeprazole, as follows:
(1) by R-4-chloro-3-hydroxyl ethyl butyrate and the DMSO accounting for its 18 times of weight, the sodiumazide of 1 times of weight stirs together, at 60 DEG C of azido reaction 5 hours, raw material primitive reaction is complete, stopped reaction, directly concentrated except desolventizing, curing at low temperatures obtains intermediate compound I; Simultaneously above solvent additionally uses DMF, n-propyl alcohol, Virahol, propyl carbinol, the trimethyl carbinol, toluene or cyclopentanol etc. and prepares intermediate compound I, and finally by nuclear-magnetism detection, obtained intermediate compound I is: 1H-NMR (300MHz, CDCl3): δ 1.42-1.73 (m, 5H) 2.76-2.67 (ABsystem, m, 2H), 3.31-3.23 (ABsystem, m, 2H), 4.40 (m, 1H), 3.70 (s, 1H).
(2) intermediate compound I that will obtain from step (1), in the ethanol of 15 times of weight of R-4-chloro-3-hydroxyl ethyl butyrate, add 10% platinum C catalyst of 0.5 times of weight, stir cooling, pass into hydrogen 60 DEG C of reduction reactions 10 hours, the weight ratio of described intermediate II and solvent is 1: 15, then collect and obtain intermediate II, above solvent additionally uses methyl alcohol simultaneously, Virahol, tetrahydrofuran (THF), DMF or DMSO etc. prepare intermediate II, detect finally by nuclear-magnetism, obtained intermediate II is: 1H-NMR (300MHz, D20): δ 1.30 (m, 3H), 2.76-2.67 (ABsystem, m, 2H, ), 3.31-3.23 (ABsystem, m, 2H), 4.12 (m, 2H), 4.40 (m, 1H), 4.70 (bs, 3H)..
(3) intermediate II that will obtain from step (2), in the ethanol of 15 times of weight of R-4-chloro-3-hydroxyl ethyl butyrate, stir cooling, drip the positive butyl ester of bromoacetic acid 60 DEG C of condensation reactions 10 hours, the mol ratio of described intermediate compound I and halogenated acetic acids ester is 1: 1.5, then collect and obtain intermediate III, above solvent additionally uses methyl alcohol simultaneously, Virahol, tetrahydrofuran (THF), DMF or DMSO etc. prepare intermediate III, detect finally by nuclear-magnetism, obtained intermediate II is: 1H-NMR (300MHz, D2O): δ 0.96 (t, 3H), 1.30-1.33 (m, 5H), 1.57 (m, 2H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s, 2H), 4.08-4.12 (m, 5H)..
(4) by intermediate III that step (3) obtains, be dissolved in ethyl acetate, the mol ratio of described intermediate III and ethyl acetate is 1: 12, ring closure reaction is carried out 6.5 hours at being warming up to 85 DEG C, obtain the solution containing intermediate compound IV, then intermediate compound IV is obtained from containing collecting the solution of intermediate compound IV, described solvent additionally uses as ethanol, the trimethyl carbinol, toluene, dimethylbenzene, water, butylacetate or ethyl butyrate, detect finally by nuclear-magnetism, obtained intermediate compound IV is: 1H-NMR (300MHz, CDCl3) δ 0.96 (t, 3H) 1.33 (m, 2H), 1.57 (m, 2H) 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H)..
(5) add in strong aqua by the intermediate compound IV that step (4) obtains, stirring at room temperature carries out ammonolysis reaction 15 hours, described intermediate compound IV: the mol ratio of ammonia is intermediate compound IV: ammonia=1: 13, in the ammonia in ammonia methanol solution; React completely concentrated removal water and ammonia, and adopt acetone purifying, crystallization obtains product (R)-Esomeprazole crude product.By dissolving crude product in water, heating for dissolving, activated carbon decolorizing, cross and filter gac, concentrating under reduced pressure dewaters, when surplus water is concentrated for stopping when adding products weight 2 ~ 3 times, 0 ~ 5 DEG C of subcooling crystallization, obtains product (R)-Esomeprazole.It is 99.9% that HPLC measures its purity, calculates yield is 38%, and detect through nuclear-magnetism, gained dextrorotation oxiracetam is: 1H-NMR (300MHz, DMSO-d6) δ 2.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.2.
Embodiment 4-13: the step of according to the form below and parameter are carried out, other identical with embodiment 1.
Step 1 table 1
Step 2
Table 2
Step 3 table 3
Step 4 table 4
Step 5
Table 5
Conclusion: utilize the acquisition target product dextrorotation oxiracetam that the route of Patent design of the present invention can be comparatively easy, and whole route does not have loaded down with trivial details column chromatography separating purification process, is applicable to suitability for industrialized production, total recovery: 38%-45%.The product obtained is checked through liquid chromatography, and purity reaches 99.9%, and isomer proportion is less than 0.1%.
Claims (13)
1. a preparation method for (R)-Esomeprazole, is characterized in that: reaction expression is as follows,
(1) with (R)-4-chloro-3-hydroxybutanoic acid ester for starting raw material, carry out azido reaction, obtain intermediate compound I;
(2) intermediate compound I is carried out reduction reaction and obtain intermediate II;
(3) intermediate II and halogenated acetic acids ester are carried out condensation reaction, obtain intermediate III;
(4) intermediate III is carried out ring closure reaction and obtain intermediate compound IV;
(5) intermediate compound IV is carried out ammonolysis reaction, obtain target product (R)-Esomeprazole.
2. the preparation method of (R)-Esomeprazole as claimed in claim 1, is characterized in that: described R1 is the alkyl of C1-C6, phenyl or benzyl; R2 is the alkyl of C1-C6, phenyl or benzyl.
3. the preparation method of (R)-Esomeprazole as claimed in claim 2, is characterized in that: the alkyl of described C1-C6 is methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, cyclopentyl or cyclohexyl.
4. the preparation method of (R)-Esomeprazole as claimed in claim 1, is characterized in that: the azide reagent that described step (1) azido reaction uses is sodiumazide, one or more mixing in Lithium Azide, potassium azide, azide calcium, barium azide.
5. the preparation method of (R)-Esomeprazole as described in any one of claim 1-4, is characterized in that: the reduction reaction of described step (2) is the one in hydroborate or hydrogen reducing.
6. the preparation method of (R)-Esomeprazole as claimed in claim 5, is characterized in that: the catalyzer of described hydrogen reducing is metal catalyst; Described metal catalyst is one or more combinations in palladium, rhodium, platinum.
7. the preparation method of (R)-Esomeprazole as described in any one of claim 1-6, is characterized in that: described halogenated acetic acids ester is chloracetic acid ester or monobromo-acetic acid ester.
8. the preparation method of (R)-Esomeprazole as claimed in claim 7, is characterized in that: described chloracetic acid ester is ethyl chloroacetate; Described monobromo-acetic acid ester is ethyl bromoacetate, the positive butyl ester of bromoacetic acid, bromide isobutyl acetate, bromo-acetic acid tert-butyl or benzyl acetate bromide.
9. the preparation method of (R)-Esomeprazole as described in any one of claim 1-8, it is characterized in that: described step (3) condensation reaction in the basic conditions, described alkali is selected from the one or more combination in pyridine, triethylamine, lutidine, salt of wormwood or sodium bicarbonate.
10. the preparation method of (R)-Esomeprazole as described in any one of claim 1-8, is characterized in that: one or more mixing in the solvent selected from methanol used in described step (1), ethanol, n-propyl alcohol, Virahol, propyl carbinol, the trimethyl carbinol, hexalin, cyclopentanol, DMF, DMSO; The mol ratio of described azide reagent and 4-chloro-3-hydroxybutanoic acid ester is: 4-chloro-3-hydroxybutanoic acid ester: azide reagent=1: 1 ~ 2.5.
11. as described in any one of claim 1-9 the preparation method of (R)-Esomeprazole, it is characterized in that: the mol ratio of intermediate II and halogenated acetic acids ester is: 1: 1 ~ 3, the mol ratio of intermediate II and described alkaline catalysts is: 1: 2 ~ 3.
12. as described in any one of claim 1 or 5 preparation method of (R)-Esomeprazole, it is characterized in that: the weight ratio of described metal catalyst and R-4-chloro-3-hydroxybutanoic acid ester is: R-4-chloro-3-hydroxybutyrate ester: metal catalyst=1: 0.1 ~ 0.5.
13. as described in any one of claim 1-9 the preparation method of (R)-Esomeprazole, it is characterized in that: the mol ratio of described intermediate III and solvent is 1: 10 ~ 30, the one or more combination in described solvent selected from ethanol, the trimethyl carbinol, toluene, dimethylbenzene, water, ethyl acetate, butylacetate or ethyl butyrate.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410386909.5A CN105330582B (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
| CN201810606694.1A CN108467355A (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410386909.5A CN105330582B (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810606694.1A Division CN108467355A (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105330582A true CN105330582A (en) | 2016-02-17 |
| CN105330582B CN105330582B (en) | 2018-08-07 |
Family
ID=55281376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810606694.1A Withdrawn CN108467355A (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
| CN201410386909.5A Active CN105330582B (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810606694.1A Withdrawn CN108467355A (en) | 2014-08-07 | 2014-08-07 | (R) preparation method of-Esomeprazole |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108467355A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107973736A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | (R)-Esomeprazole crystal form and its preparation method and application |
| CN107973739A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam crystal form II and its preparation method and application |
| CN107973737A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam novel crystal forms and its preparation method and application |
| CN107973740A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | A kind of dextrorotation oxiracetam compound and its preparation method and application |
| CN109251157A (en) * | 2017-07-13 | 2019-01-22 | 重庆润泽医药有限公司 | (R)-Esomeprazole preparation method |
| US10961192B2 (en) | 2017-01-12 | 2021-03-30 | Chongqing Ruzer Pharmaceutical Company Limited | (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513836A (en) * | 2002-06-22 | 2004-07-21 | 张家港浩波化学品有限公司 | Method of preparing 4-hydroxy pyrrolidone-2-acetamine |
| KR101008364B1 (en) * | 2008-03-14 | 2011-01-13 | 엔자이텍 주식회사 | Process for preparing racemic or optically pure S-oxiracetam |
| CN102603607A (en) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | Preparation method of (R)-oxiracetam |
| CN103351322A (en) * | 2013-07-03 | 2013-10-16 | 广安凯特医药化工有限公司 | Synthetic method of oxiracetam |
| CN103553999A (en) * | 2013-11-06 | 2014-02-05 | 重庆润泽医药有限公司 | Preparation method of (S)-oxiracetam crystal form III |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100679633B1 (en) * | 2004-07-27 | 2007-02-07 | 한국화학연구원 | Process for preparation of s or r-oxiracetam |
| CN101121688A (en) * | 2007-09-14 | 2008-02-13 | 南开大学 | Improved method for synthesizing oxiracetam |
| CN103553998B (en) * | 2013-11-06 | 2015-11-25 | 温州智创科技有限公司 | (S) preparation method of-Oxiracetam crystal form III |
| CN103553997B (en) * | 2013-11-06 | 2015-11-25 | 温州智创科技有限公司 | The preparation method of a kind of (S)-Oxiracetam crystal form III |
-
2014
- 2014-08-07 CN CN201810606694.1A patent/CN108467355A/en not_active Withdrawn
- 2014-08-07 CN CN201410386909.5A patent/CN105330582B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513836A (en) * | 2002-06-22 | 2004-07-21 | 张家港浩波化学品有限公司 | Method of preparing 4-hydroxy pyrrolidone-2-acetamine |
| KR101008364B1 (en) * | 2008-03-14 | 2011-01-13 | 엔자이텍 주식회사 | Process for preparing racemic or optically pure S-oxiracetam |
| CN102603607A (en) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | Preparation method of (R)-oxiracetam |
| CN103351322A (en) * | 2013-07-03 | 2013-10-16 | 广安凯特医药化工有限公司 | Synthetic method of oxiracetam |
| CN103553999A (en) * | 2013-11-06 | 2014-02-05 | 重庆润泽医药有限公司 | Preparation method of (S)-oxiracetam crystal form III |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018076784A1 (en) * | 2016-10-24 | 2018-05-03 | 重庆润泽医药有限公司 | Crystalline form of (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof |
| JP2019536751A (en) * | 2016-10-24 | 2019-12-19 | チョンキン ランゼ ファーマスーティカル カンパニー リミテッド | Type 2 crystal of dextrorotatory oxiracetam, preparation method and use |
| CN107973737A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam novel crystal forms and its preparation method and application |
| CN107973740A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | A kind of dextrorotation oxiracetam compound and its preparation method and application |
| WO2018076782A1 (en) * | 2016-10-24 | 2018-05-03 | 重庆润泽医药有限公司 | Novel crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
| WO2018076783A1 (en) * | 2016-10-24 | 2018-05-03 | 重庆润泽医药有限公司 | Crystalline form ii of dextral oxiracetam, preparation method therefor and use thereof |
| CN107973739A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam crystal form II and its preparation method and application |
| US10793521B2 (en) | 2016-10-24 | 2020-10-06 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof |
| CN107973736A (en) * | 2016-10-24 | 2018-05-01 | 重庆润泽医药有限公司 | (R)-Esomeprazole crystal form and its preparation method and application |
| US10556863B1 (en) | 2016-10-24 | 2020-02-11 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof |
| CN107973739B (en) * | 2016-10-24 | 2020-03-20 | 重庆润泽医药有限公司 | Dextro-oxiracetam crystal form II and preparation method and application thereof |
| CN107973737B (en) * | 2016-10-24 | 2020-03-24 | 重庆润泽医药有限公司 | Novel dextro-oxiracetam crystal form and preparation method and application thereof |
| US10696629B2 (en) | 2016-10-24 | 2020-06-30 | Chongqing Runze Pharmaceutical Company Limited | Crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
| US10961192B2 (en) | 2017-01-12 | 2021-03-30 | Chongqing Ruzer Pharmaceutical Company Limited | (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof |
| CN109251157A (en) * | 2017-07-13 | 2019-01-22 | 重庆润泽医药有限公司 | (R)-Esomeprazole preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105330582B (en) | 2018-08-07 |
| CN108467355A (en) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106146379B (en) | A kind of synthetic method of Oxiracetam | |
| CN105330582A (en) | Preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide | |
| CN101575309B (en) | Method for synthesizing (S)-oxiracetam | |
| CN105330581A (en) | Preparation method for (S)-oxiracetam | |
| CN102153585B (en) | Synthesis method of minodronate midbody and synthesis of minodronate | |
| CN101941969B (en) | Preparation method of moxifloxacin hydrochloride | |
| CN101565406A (en) | Preparation process for cyproconazole | |
| CN102127005B (en) | Intermediate of alvimopan and synthesis method thereof | |
| CN103664912B (en) | A kind of synthesis technique of prucalopride | |
| CN103204819B (en) | Deuterated diazepam and preparation method thereof | |
| CN102060860B (en) | Preparation method of Marbofloxacin | |
| CN100591649C (en) | Method of preparing R-(+)-3-chlorophenylpropanol | |
| CN103554031B (en) | Preparation method of azilsartan intermediate | |
| CN102485723A (en) | Semi-synthesis of vinpocetine through one kettle way and preparation of water-soluble vinpocetine salt | |
| CN102850347A (en) | Resolution method for pyrazole derivative or salt thereof | |
| CN104193643B (en) | For the synthesis of the intermediate of anti-AIDS drug toughener cobicistat | |
| CN104557674B (en) | The preparation method of the hydroxy piperidines of one kind (S) N Boc 3 | |
| CN101270124B (en) | Novel method for purifying and preparing high-purity fluorandiol and fluorandiol salt | |
| CN102432516A (en) | Method for refining oxiracetam | |
| CN105439936A (en) | Oxiracetam preparation method | |
| CN102030707A (en) | Method for preparing Blonanserin intermediate | |
| CN103204856B (en) | Deuterated alprazolam and preparation method thereof | |
| CN102746178B (en) | The preparation method of flutamide | |
| CN103204810A (en) | Tolvaptan intermediate and preparation method thereof | |
| CN111333529A (en) | Preparation method of pregabalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170823 Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 400030 Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Applicant before: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |